X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7) 7
oncology (7) 7
hematology (5) 5
middle aged (5) 5
multiple myeloma (5) 5
aged (4) 4
care and treatment (4) 4
chemotherapy (4) 4
index medicus (4) 4
male (4) 4
melphalan (4) 4
therapy (4) 4
adult (3) 3
diagnosis (3) 3
female (3) 3
health aspects (3) 3
lenalidomide (3) 3
multiple myeloma - drug therapy (3) 3
multiple myeloma - therapy (3) 3
stem cell transplantation (3) 3
stem-cell transplantation (3) 3
thalidomide - analogs & derivatives (3) 3
transplantation (3) 3
transplantation, autologous (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
autografts (2) 2
bortezomib (2) 2
dexamethasone (2) 2
hematology, oncology and palliative medicine (2) 2
induction therapy (2) 2
initial treatment (2) 2
mobilization (2) 2
multiple myeloma - mortality (2) 2
multiple-myeloma (2) 2
myeloma (2) 2
neutropenia - chemically induced (2) 2
patient outcomes (2) 2
plus dexamethasone (2) 2
prednisone (2) 2
research (2) 2
stem cells (2) 2
thalidomide (2) 2
thalidomide - therapeutic use (2) 2
trial (2) 2
abridged index medicus (1) 1
acute disease (1) 1
acute myeloid leukemia (1) 1
administration, oral (1) 1
aged, 80 and over (1) 1
antigens, cd34 - analysis (1) 1
antineoplastic agents (1) 1
antineoplastic agents, alkylating - administration & dosage (1) 1
antineoplastic agents, alkylating - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - toxicity (1) 1
ara-c (1) 1
autologous stem cell transplantation (1) 1
autologous transplantation (1) 1
autologous transplantation, multiple myeloma (1) 1
avascular necrosis (1) 1
blood progenitor cells (1) 1
bmt (1) 1
bone density conservation agents - therapeutic use (1) 1
bone diseases - drug therapy (1) 1
bone diseases - etiology (1) 1
bone diseases - pathology (1) 1
bortezomib - therapeutic use (1) 1
bortezomib-thalidomide-dexamethasone (1) 1
campath-1h (1) 1
cancer (1) 1
cancer-chemotherapy (1) 1
cd34 cells (1) 1
cell survival (1) 1
cerebellar diseases - chemically induced (1) 1
cerebellar diseases - microbiology (1) 1
cerebellar diseases - therapy (1) 1
chemokine cxcl12 (1) 1
chronic lymphocytic leukemia (1) 1
cisplatin (1) 1
cisplatin - administration & dosage (1) 1
clinical trials (1) 1
clinical trials, phase iii as topic (1) 1
clodronic acid - therapeutic use (1) 1
collection (1) 1
combination therapy (1) 1
combined modality therapy (1) 1
complications and side effects (1) 1
consolidation chemotherapy (1) 1
consolidation therapy (1) 1
contraindications (1) 1
cyclophosphamide (1) 1
cyclophosphamide - administration & dosage (1) 1
dcep (1) 1
death (1) 1
dexamethasone - administration & dosage (1) 1
dexamethasone - therapeutic use (1) 1
diphosphonates - adverse effects (1) 1
diphosphonates - therapeutic use (1) 1
disease-free survival (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 10, pp. 895 - 905
In patients 65 or younger with multiple myeloma, high-dose consolidation therapy was associated with longer survival and more myelotoxicity than... 
MEDICINE, GENERAL & INTERNAL | PREDNISONE | PLUS DEXAMETHASONE | INDUCTION THERAPY | LENALIDOMIDE | INITIAL TREATMENT | RANDOMIZED CONTROLLED-TRIAL | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Transplantation, Autologous | Consolidation Chemotherapy | Antineoplastic Agents, Alkylating - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Melphalan - adverse effects | Adult | Maintenance Chemotherapy | Neutropenia - chemically induced | Thalidomide - adverse effects | Prednisone - administration & dosage | Prednisone - adverse effects | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Aged | Antineoplastic Agents, Alkylating - adverse effects | Stem Cell Transplantation - adverse effects | Complications and side effects | Care and treatment | Patient outcomes | Multiple myeloma | Stem cells | Transplantation | Research | Health aspects | Autografts | Chemotherapy | Cell survival | Transplants & implants | Melphalan | Stem cell transplantation | Death | Prednisone | Drug dosages | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 12/2005, Volume 36, Issue 11, pp. 951 - 954
Journal Article
CANCERS, ISSN 2072-6694, 11/2019, Volume 11, Issue 11, p. 1735
We conducted a pooled analysis of two phase III trials, RV-MM-EMN-441 and EMN01, to compare maintenance with lenalidomide-prednisone vs. lenalidomide in newly... 
MULTIPLE-MYELOMA | multiple myeloma | DEXAMETHASONE | AUTOLOGOUS TRANSPLANTATION | THALIDOMIDE | ORAL IXAZOMIB | newly diagnosed | THERAPY | ONCOLOGY | lenalidomide | prednisone | STEM-CELL TRANSPLANTATION | maintenance | MELPHALAN | SURVIVAL OUTCOMES | DURATION
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.